GUAIFENESIN (guaifenesin) by Design Pharmaceuticals. Approved for expectorant [epc]. First approved in 2018.
Drug data last refreshed 20h ago
Expectorant
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting Conditions
Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment
Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI)
Exploratory Efficacy Study of Guaifenesin in Upper Back Pain
The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study
Worked on GUAIFENESIN at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.